Unichem Pharmaceuticals recalled 230 bottles of Cyclobenzaprine Hydrochloride Tablets on August 27, 2025. The recall stems from a labeling mix-up with Meloxicam tablets, which could lead to serious health risks. Consumers should stop using the product immediately and contact their healthcare provider.
Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets USP, 10 mg 90-count tablets (blue in color).
Consumers and healthcare providers should stop using this product immediately. Contact Unichem Pharmaceuticals USA Inc. or your healthcare provider for guidance. Notification method: Press Release
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Cyclobenzaprine Hydrochloride Tablets, USP, 10 mg, in 90-count bottles. It was manufactured by Unichem Laboratories, Ltd. and distributed nationwide in the USA.
The recall was initiated due to a labeling error that mixed up Cyclobenzaprine Hydrochloride Tablets with Meloxicam USP, 7.5 mg tablets. This mix-up poses a risk of patients receiving the wrong medication, which could lead to adverse health effects.
As of the recall date, no injuries have been reported. However, the potential for misuse of the medication due to labeling confusion remains a serious concern.
Consumers should stop using the recalled tablets immediately. Contact Unichem Pharmaceuticals USA Inc. or your healthcare provider for further guidance and information on returning the product.
For further assistance, consumers can reach Unichem Pharmaceuticals at their official website or by calling customer service.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.